Form 4: Acumen CEO Sells Shares for Tax Obligations

Acumen Pharmaceuticals CEO Daniel O'Connell sold common stock totaling 47,506 shares across three transactions in early January 2026 to cover tax withholding obligations.

Summary

• Daniel Joseph O'Connell, Acumen Pharmaceuticals, Inc.'s Director and Chief Executive Officer, reported the sale of common stock.
• The sales occurred on January 5, 2026, January 6, 2026, and January 7, 2026.
• A total of 4,649 shares were sold on January 5, 2026, at a weighted average price of $1.971 per share.
• A total of 5,102 shares were sold on January 6, 2026, at a weighted average price of $1.9662 per share.
• A total of 37,755 shares were sold on January 7, 2026, at a weighted average price of $1.986 per share.
• These transactions were automatic 'sell to cover' sales to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. O'Connell on June 24, 2024.
• Following these transactions, Mr. O'Connell beneficially owns 619,982 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are routine 'sell to cover' sales for tax withholding purposes, executed under a pre-established 10b5-1 plan, and are not indicative of discretionary selling or a change in management's outlook on the company.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing equity compensation and tax obligations.
• The vesting of restricted stock units implies the achievement of certain performance metrics or tenure requirements by the CEO.

Negatives

• The sales resulted in a reduction of the CEO's direct beneficial ownership of common stock by 47,506 shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sales represent the number of shares sold by the Reporting Person through an automatic 'sell to cover' transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not provide specific insights into Acumen Pharmaceuticals' operational performance or broader industry trends.

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in the CEO's direct beneficial ownership, but for a routine, non-discretionary reason, which typically has minimal impact on investor perception.
• Employees: The vesting of restricted stock units is a standard form of equity compensation, aligning employee interests with company performance.

Key Dates

Recommendation

The reported transactions are routine 'sell to cover' sales by the CEO to satisfy tax withholding obligations upon the vesting of restricted stock units, executed under a pre-established 10b5-1 trading plan. Such transactions are generally not indicative of management's view on the company's future prospects and do not typically warrant a change in investment recommendation.

Keywords

Acumen Pharmaceuticals, ABOS, Form 4, Insider Transaction, CEO Stock Sale, Restricted Stock Units, 10b5-1 Plan, Tax Withholding